However, among patients with coronary artery diseases, statistically, significant differences were observed only between low-risk and high-risk strata regarding the use of angiotensin-converting enzyme inhibitors (ACEI), beta blockers and oral antidiabetics other than sodium-glucose co-transporter-2 inhibitors (SGLT2-inhibitors) and metformin. The gene discussed is ACE; the disease is coronary artery disorder.